Alvimopan
- Generic Name
- Alvimopan
- Brand Names
- Entereg
- Drug Type
- Small Molecule
- Chemical Formula
- C25H32N2O4
- CAS Number
- 156053-89-3
- Unique Ingredient Identifier
- Q153V49P3Z
- Background
Alvimopan is a peripherally acting μ opioid antagonist. It is used to avoid postoperative ileus following small or large bowel resection and accelerates the gastrointestinal recovery period.
- Indication
用于手术以及使用阿片类药物导致的胃肠功能紊乱，特发性便秘以及肠易激综合症等。
- Associated Conditions
- -
- Associated Therapies
- Gastrointestinal Recovery
Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2017-08-30
- Target Recruit Count
- 805
- Registration Number
- NCT00241722
- Locations
- 🇬🇧
GSK Investigational Site, Yaxley, Peterborough, United Kingdom
Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2016-01-11
- Target Recruit Count
- 660
- Registration Number
- NCT00205842
- Locations
- 🇺🇸
50 Sites, Exton, Pennsylvania, United States
Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2015-09-02
- Target Recruit Count
- 67
- Registration Number
- NCT00135577
- Locations
- 🇬🇧
GSK Investigational Site, Nottingham, United Kingdom
Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication
- First Posted Date
- 2005-01-19
- Last Posted Date
- 2017-08-30
- Target Recruit Count
- 233
- Registration Number
- NCT00101998
- Locations
- 🇬🇧
GSK Investigational Site, Surrey, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath